Advancing RNA
Online/Digital
Advancing RNA is a Life Science Connect community focused on the rapidly evolving field of RNA-based therapeutics. It aims to provide valuable insights, discussions, and resources for professionals developing RNA-based drugs. Primary members of the community consist of individuals from biopharma organizations engaged in pre-BLA development, often in the pre-IND discovery stage. The community addresses various challenges in RNA therapy development, including analytical, quality, manufacturing, and regulatory issues. Additionally, Advancing RNA is positioned within the broader Life Science Connect network, allowing members to access additional resources as needed for their RNA therapy development journey. Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search Articles08.26.26 -- The 3 Pillars Of Next-Gen mRNA Expansion
This Advancing RNA discussion will be a deep dive into the world of plasmid sourcing and quality considerations. What quality attributes matter the most for producing the desired quality of mRNA? What are the current gaps in our knowledge of plasmid quality, and how are we as an industry striving to close these gaps? Register today and find out.
From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2)
A conversation with Samir Ounzain, Ph.D., CEO & Scientific Cofounder, HAYA Therapeutics In Part 1 of his conversation with Life Science Connect Acquisition Editor Michael Soloway, HAYA Therapeutics CEO and scientific cofounder Samir Ounzain, Ph.D., argued that the future of RNA medicine may lie not in targeting individual proteins but in reprogramming the regulatory networks that determine cellular identity. That vision is beginning to move beyond theory.
What Baby KJ Taught Us About mRNA COGS
By Anna Rose Welch, Editorial & Community Director, Advancing RNA Over the past few weeks, I’ve been publishing a series of articles from the AMM/Franklin Biolabs event, “Building RNA Medicine Excellence.” In my first takeaway from this event, I discussed three core pillars of expansion for the mRNA industry.
Unified Lab Software For Modern QC Workflows
Chromatography workflows are becoming more complex, with larger data sets, higher-resolution methods, and growing demands for reliable results. Agilent OpenLab CDS provides secure data management, instrument control, analysis, and reporting within a scalable, end-to-end chromatography data system. Designed to support operations ranging from single instruments to global laboratories, it accommodates routine testing as well as high-impact characterization.
Full-Spectrum Bio LC
Bioanalysis demands liquid chromatography solutions that can handle sensitive biomolecules while supporting reliable, reproducible results. Agilent InfinityLab Bio LC Solutions bring together fully biocompatible and bio-inert LC systems with complementary mass spectrometry detection, bio columns, software, and services.
MilliporeSigma Capabilities Update August 2026: Nanoparticles
Bringing lipid-based therapies from early development to commercialization requires specialized expertise, scalable infrastructure, and coordinated support. MilliporeSigma’s end-to-end CDMO capabilities span lipid manufacturing, lipid nanoparticle formulation, process development, analytical testing, aseptic fill and finish, and supply chain management.
Considerations And Strategies For Oligonucleotide Manufacturing Scale-Up
Get more Advancing RNA insight with our FREE newsletter Source: Asahi Kasei Bioprocess By George Flores, Technical Solutions Manager, Asahi Kasei Bioprocess Oligonucleotide therapeutics are revolutionizing the way scientists target molecules that are beyond the reach of conventional drugs.
Agilent Altura SEC HPLC Columns With Ultra Inert Technology
Size exclusion chromatography methods can be complicated by unwanted interactions between analytes and the stationary phase. Agilent Altura SEC combines the stationary phase used in the AdvanceBio SEC portfolio with Ultra Inert technology to minimize these secondary interactions. By reducing the need to compensate for column-related effects, it gives scientists greater freedom to optimize method conditions around the characteristics of their samples.
Targeted LNPs: From Ligand Conjugation & Preclinical Screening To Process Optimization And Scale-Up
Webinar | August 20, 2026 Targeted lipid nanoparticles (tLNPs) offer a promising route to deliver nucleic acid payloads to specific cells and tissues beyond the liver. Achieving that precision requires the careful selection and covalent conjugation of targeting ligands, including full-length antibodies, antibody fragments, VHH nanobodies, and peptides. It also depends on analytical methods capable of evaluating critical quality attributes throughout development.
08.19.26 -- 5 Critical Regulatory Topics To Watch In The Oligo Sector
This Advancing RNA discussion will be a deep dive into the world of plasmid sourcing and quality considerations. What quality attributes matter the most for producing the desired quality of mRNA? What are the current gaps in our knowledge of plasmid quality, and how are we as an industry striving to close these gaps? Register today and find out.